Table 1.
Characteristics of patients ≥ 18 year receiving HLA-identical sibling donor transplants for CML in first chronic phase, reported to the CIBMTR, 1990–2004.
| Non Smokers | Smokers |
|||||
|---|---|---|---|---|---|---|
| Low dosea | High dosea | |||||
| Variables | N | N (%) | N | N (%) | N | N (%) |
| Number of patients | 1649 | 370 | 94 | |||
| Age at transplant, years, median (range) | 1649 | 37 (18–61) | 370 | 38 (18–66) | 94 | 45 (22–58) |
| Age at transplant, years | 1649 | 370 | 94 | |||
| 18 – 29 | 419 (25) | 67 (18) | 6 (6) | |||
| 30 – 39 | 580 (35) | 134 (36) | 22 (23) | |||
| 40 – 49 | 466 (28) | 115 (31) | 48 (51) | |||
| ≥50 | 184 (11) | 54 (15) | 18 (19) | |||
| Male | 1649 | 888 (54) | 370 | 262 (71) | 94 | 68 (72) |
| Region | 1648 | 370 | 94 | |||
| United States | 499 (30) | 126 (34) | 53 (56) | |||
| Canada | 60 (4) | 14 (4) | 8 (9) | |||
| Europe | 594 (36) | 141 (38) | 20 (21) | |||
| Asia | 143 (9) | 20 (5) | 4 (4) | |||
| Australia/New Zealand | 88 (5) | 13 (4) | 3 (3) | |||
| Mideast/Africa | 139 (8) | 12 (3) | 3 (3) | |||
| Central/South America | 125 (8) | 44 (12) | 3 (3) | |||
| Karnofsky score (< 90%) | 1637 | 171 (10) | 366 | 42 (11) | 92 | 15 (16) |
| Number of packs per day | 370 | 94 | ||||
| ≤1 | -- | 363 (98) | -- | |||
| > 1 | -- | 7 (2) | 94 (100) | |||
| Number of years smoked, median (range) | -- | 370 | 12 (1–43) | 94 | 20 (5–44) | |
| Smoking pack-year, median (range) | -- | 370 | 10 (<1–3) | 94 | 34 (12–140) | |
| Smoking pack-year, | 370 | 94 | ||||
| ≤10 pack-year | -- | 222 (60) | -- | |||
| > 10 pack-year | -- | 148 (40) | 94 (100) | |||
| Body mass index, kg/m2 | 1635 | 369 | 94 | |||
| ≤22 | 380 (23) | 69 (19) | 19 (20) | |||
| 22–30 | 1012 (62) | 238 (64) | 59 (63) | |||
| > 30 | 243 (15) | 62 (17) | 16 (17) | |||
| White cell count at diagnosis, 109/L, median (range) | 1529 | 145 (1–800) | 347 | 114 (7–650) | 89 | 96 (4–387) |
| White cell count at diagnosis, 109/L | 1529 | 347 | 89 | |||
| < 50 | 282 (18) | 91 (26) | 26 (29) | |||
| 50 – 100 | 290 (19) | 68 (20) | 24 (27) | |||
| > 100 | 957 (63) | 188 (54) | 39 (44) | |||
| Spleen size at diagnosis | 1477 | 342 | 81 | |||
| Normal | 467 (32) | 127 (37) | 31 (38) | |||
| Enlarged | 1010 (68) | 215 (63) | 50 (62) | |||
| Coexisting diseases | 1646 | 369 | 94 | |||
| Cardiac and Pulmonary | 9 (1) | 2 (1) | 4 (4) | |||
| Cardiac | 107 (7) | 32 (9) | 14 (15) | |||
| Pulmonary | 28 (2) | 12 (3) | 7 (7) | |||
| Other | 214 (13) | 60 (16) | 20 (21) | |||
| None | 1288 (78) | 263 (71) | 49 (52) | |||
| Pre-transplant therapy for CML | ||||||
| Hydroxyurea | 1634 | 1510 (92) | 368 | 333 (90) | 94 | 78 (83) |
| Interferon | 1205 | 578 (48) | 269 | 127 (47) | 75 | 33 (44) |
| Imatinib | 1648 | 50 (3) | 370 | 9 (2) | 94 | 4 (4) |
| Time from diagnosis to transplant, months, median (range) | 1649 | 8 (<1–127) | 370 | 9 (1–72) | 94 | 7 (2–99) |
| Time from diagnosis to transplant, months | 1649 | 370 | 94 | |||
| < 6 | 522 (32) | 108 (29) | 38 (40) | |||
| 6 – 11 | 591 (36) | 138 (37) | 31 (33) | |||
| 12 – 23 | 380 (23) | 90 (24) | 18 (19) | |||
| ≥24 | 156 (9) | 34 (9) | 7 (7) | |||
| EBMT Risk Score | 1647 | 370 | 94 | |||
| 0–1 | 572 (35) | 92 (25) | 16 (17) | |||
| 2 | 717 (44) | 171 (46) | 48 (51) | |||
| 3 | 322 (20) | 91 (25) | 26 (28) | |||
| 4 | 36 (2) | 16 (4) | 4 (4) | |||
| Year of transplant | 1649 | 370 | 94 | |||
| 1990 – 1994 | 746 (45) | 155 (42) | 44 (47) | |||
| 1995 – 1999 | 655 (40) | 173 (47) | 44 (47) | |||
| 2000 – 2004 | 248 (15) | 42 (11) | 6 (6) | |||
| Conditioning regimen | 1649 | 370 | 94 | |||
| TBI/Cy ± other | 591 (36) | 124 (34) | 36 (38) | |||
| Bu/Cy ± other (no TBI) | 1058 (64) | 246 (66) | 58 (62) | |||
| Dose of Cyb, mg/kg | 1432 | 320 | 76 | |||
| 120 | 1267 (88) | 279 (87) | 65 (86) | |||
| 200 | 165 (12) | 41 (13) | 11 (14) | |||
| Dose of Bu, mg/kg | 1627 | 366 | 93 | |||
| No Bu | 591 (36) | 124 (34) | 36 (39) | |||
| < 12 | 59 (4) | 6 (2) | 5 (5) | |||
| 12–16 | 304 (19) | 72 (20) | 23 (25) | |||
| 16–17 | 613 (38) | 157 (43) | 25 (27) | |||
| ≥17 | 60 (4) | 7 (2) | 4 (4) | |||
| Dose of TBI, cGy | 1603 | 352 | 86 | |||
| Non-TBI | 1058 (66) | 246 (70) | 58 (67) | |||
| <1300 | 421 (26) | 79 (22) | 18 (21) | |||
| ≥1300 | 124 (8) | 27 (8) | 10 (12) | |||
| GVHD prophylaxis | 1649 | 370 | 94 | |||
| T depl ± other | 102 (6) | 25 (7) | 9 (10) | |||
| FK506 ± other | 58 (4) | 10 (3) | 4 (4) | |||
| MTX + CsA ± other | 1324 (80) | 293 (79) | 66 (70) | |||
| CsA ± other (no MTX) | 165 (10) | 42 (11) | 15 (16) | |||
| Donor age | 1580 | 352 | 88 | |||
| ≤29 | 460 (29) | 73 (21) | 8 (9) | |||
| 30 – 39 | 534 (34) | 123 (35) | 25 (28) | |||
| 40 – 49 | 405 (26) | 98 (28) | 40 (45) | |||
| ≥50 | 181 (11) | 58 (16) | 15 (17) | |||
| Gender match | 1647 | 370 | 94 | |||
| Male into male | 523 (32) | 141 (38) | 43 (46) | |||
| Male into female | 405 (25) | 55 (15) | 16 (17) | |||
| Female into male | 365 (22) | 121 (33) | 25 (27) | |||
| Female into female | 354 (21) | 53 (14) | 10 (11) | |||
| Donor-Recipient CMV status | 1555 | 350 | 91 | |||
| −/− | 391 (25) | 89 (25) | 24 (26) | |||
| −/+ | 200 (13) | 45 (13) | 14 (15) | |||
| +/− | 183 (12) | 40 (11) | 10 (11) | |||
| +/+ | 781 (50) | 176 (50) | 43 (47) | |||
| Graft type | 1649 | 370 | 94 | |||
| BM | 1331 (81) | 301 (81) | 78 (83) | |||
| PB ± BM | 318 (19) | 69 (19) | 16 (17) | |||
| Use of ATG or Campath | 1627 | 15 (1) | 365 | 3 (1) | 94 | 4 (4) |
| Lung shielding in radiation therapy | 1587 | 262 (17) | 360 | 50 (14) | 92 | 11 (12) |
| Follow-up of surviving patients, month | 1649 | 91 (2–209) | 370 | 98 (1–199) | 94 | 115 (19–193) |
Abbreviations: CML = chronic myelogenous leukemia; TBI = total body irradiation; Cy = cyclophosphamide; Bu = busulfan; GVHD = graft-versus-host disease; MTX = methotrexate; CsA = cyclosporine; BM=Bone marrow; PB=Peripheral blood.
a
Low dose smokers=smoking ≤ 10 pack-years or > 10 pack-years with 1 ≤ pack/day; high dose smokers=smoking ≥ 10 pack-years with > 1 pack/day.
b
Cy dose range 100–150 mg/kg classified as 120 mg/kg; Cy dose ≥ 150 mg/kg classified as 200 mg/kg.
Duration of follow-up:
Non-smoker: ≥ 1 year = 73%; ≥ 3 year = 61%; ≥ 5 year = 50%.
Low dose smoker: ≥ 1 year = 69%; ≥ 3 year = 59%; ≥ 5 year = 49%.
High dose smoker: ≥ 1 year = 70%; ≥ 3 year = 46%; ≥ 5 year = 45%.